

**Attachments
To Witness Truth In Testimony Form
For
Sir Menelas Pangalos, Ph.D.**

**Subcommittee on Oversight and Investigations
Committee on Energy and Commerce
U.S. House of Representatives**

**Pathway to a Vaccine:
Efforts to Develop a Safe, Effective and Accessible COVID-19 Vaccine**

July 21, 2020

ATTACHMENT 1

FEDERAL GRANTS OR CONTRACTS

1. Advanced Agreement, dated May 20, 2020, between the US Biomedical Advanced Research and Development Authority (BARDA) and AstraZeneca PLP, wherein the parties agreed to enter into a definitive agreement for procurement by BARDA of 300 million doses of the AZD1222 COVID-19 vaccine. Agreement value is estimated at \$1.2 billion USD.
2. Agreement, dated June 2, 2020, between BARDA, the US Defense Advanced Research Projects Agency (DARPA), and AstraZeneca, to support AstraZeneca's efforts to develop a monoclonal antibody treatment against COVID-19. Agreement value is estimated at \$25.1 million USD.

ATTACHMENT 2

CONTRACTS OR PAYMENTS ORIGINATING WITH A FOREIGN GOVERNMENT

1. AstraZeneca is currently negotiating a final agreement with the United Kingdom Government to supply the AZD1222 COVID-19 vaccine. The estimated funding under this agreement is subject to further negotiations and has not been finalized. AstraZeneca has also entered into a Research Collaboration and Exclusive Worldwide Patent And Know-How License, dated May 17, 2020, with Oxford University Innovation Limited (“OUI”) for the global development, manufacture, and distribution of the AZD1222 COVID-19 vaccine. Although AstraZeneca is not receiving funding from the UK Government under the OUI agreement, we are aware that the UK government partially funded OUI’s research activities.
2. AstraZeneca is currently negotiating a final agreement with the Federal Republic of Germany, French Republic, Italian Republic, and the Kingdom of the Netherlands to supply 300 million doses of the AZD1222 COVID-19 vaccine. The agreement remains subject to further negotiations.
3. AstraZeneca has entered into agreements with the Coalition for Epidemic Preparedness Innovations (CEPI) and the GAVI Alliance to support the manufacturing, procurement, and distribution of 300 million doses of the AZD1222 COVID-19 vaccine. The agreement value is estimated at \$750 million USD. Although these organizations receive foreign government funding, AstraZeneca does not know what portion of the estimated agreement funding originated with foreign governments.
4. AstraZeneca is currently in negotiations with other countries; however, the final terms and estimated value of these potential contracts are not available at this time.